Mr. Speaker, in budget 2022, the Government of Canada committed to continue its ongoing work towards a universal national pharmacare program. This will include tabling a Canada pharmacare bill, and then tasking the Canadian drug agency to develop a national formulary of essential medicines and bulk purchasing plan.
The nature of the bill is still under discussion, and we are not able to confirm either any specific approach to national pharmacare or any potential future investments at this time.
That said, the Government of Canada has made important investments to date to support the implementation of national pharmacare. The government announced its intention to move forward, in partnership with provinces, territories, and other partners and stakeholders, on foundational elements of national pharmacare, including the following.
First is the creation of the Canadian drug agency, or CDA, supported by $89.5 million over five years, in addition to the existing federal funding of $34.2 million annually to support the Canadian Agency for Drugs and Technologies in Health. The CDA will provide the dedicated leadership and coordination needed to make Canada's drug system more sustainable and better prepared for the future, helping Canadians achieve better health outcomes.
Second is the launch of the first-ever national strategy for drugs for rare diseases, supported by investments of up to $1.5 billion over three years. This first phase aims to increase access to and affordability of effective drugs for rare diseases, which will contribute to improving the health of patients across Canada.
Third are enhancements to Prince Edward Island’s public drug programs, supported by $35 million to provide its residents with more affordable access to prescription drugs and to inform next steps on national universal pharmacare.